Buchumschlag

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sejung Hwang, Yujin Lee, Yeonseo Jang, Joo‐Youn Cho, Seonghae Yoon, Jae‐Yong Chung
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Clinical Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
von: Cornelius Cilliers, et al.
Veröffentlicht: (2024)

Effects of GLPG3970 on Sulfasalazine and Methotrexate Pharmacokinetics in Healthy Adults: Two Open‐Label, Phase I, Drug–Drug Interaction Studies
von: Mariska van der Plas, et al.
Veröffentlicht: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
von: Yi‐An Bi, et al.
Veröffentlicht: (2024)

A Clinical Practice Perspective on the Evaluation of OATP1B1‐associated Drug Interactions
von: Céline K. Stäuble, et al.
Veröffentlicht: (2024)

Biomarker‐Based Prediction of OATP1B1 Activity in Clinical Routine—Investigating Coproporphyrins as Markers for Drug–Drug–Gene Interactions
von: Leila Potzel, et al.
Veröffentlicht: (2026)

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug–Drug Interaction Study
von: Joseph Burnett, et al.
Veröffentlicht: (2025)

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID‐19 Patients with CYP2C19 Phenotypes
von: Peile Wang, et al.
Veröffentlicht: (2024)

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
von: Roberto Viviani, et al.
Veröffentlicht: (2024)

Microdose Cocktail Study Reveals the Activity and Key Influencing Factors of OATP1B , P‐Gp, BCRP, and CYP3A in End‐Stage Renal Disease Patients
von: Weijie Kong, et al.
Veröffentlicht: (2025)

Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study
von: Anne‐Kristina Mercier, et al.
Veröffentlicht: (2024)

Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
von: Jie Shao, et al.
Veröffentlicht: (2024)

Discovering Severe Adverse Reactions From Pharmacokinetic Drug–Drug Interactions Through Literature Analysis and Electronic Health Record Verification
von: Eugene Jeong, et al.
Veröffentlicht: (2024)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
von: Simeon Rüdesheim, et al.
Veröffentlicht: (2025)

Prediction of Local Drug Exposure of Dry Powder Inhaler CXG87 (budesonide/formoterol) Using Physiologically‐Based Pharmacokinetic Model
von: Yuran Cao, et al.
Veröffentlicht: (2025)

New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
von: Arne Gessner, et al.
Veröffentlicht: (2024)

Drug Interactions Brewing
von: Matthijs W. van Hoogdalem, et al.
Veröffentlicht: (2025)

Country Contribution to Investigators of Pivotal Clinical Trials and Their Primary Publications of New Drugs Approved by the US Food and Drug Administration, 2012–2021
von: Yoona Choi, et al.
Veröffentlicht: (2025)

Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
von: Chi‐Chi Peng, et al.
Veröffentlicht: (2025)

Population Pharmacokinetic Modeling of Glycochenodeoxycholic Acid 3‐O‐Sulfate ( GCDCA ‐S) as Endogenous Biomarker of OATP1B3 and OAT3 Transporters
von: Yuki Ujihira, et al.
Veröffentlicht: (2025)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
von: Emanuel Raschi, et al.
Veröffentlicht: (2025)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
von: Emily K. Acton, et al.
Veröffentlicht: (2024)

Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
von: Elpida Kontsioti, et al.
Veröffentlicht: (2024)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
von: Kenza Abouir, et al.
Veröffentlicht: (2024)

Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
von: Norah Mwebaza, et al.
Veröffentlicht: (2024)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
von: Kunal S. Taskar, et al.
Veröffentlicht: (2025)

Assessing Post‐Marketing Requirements for Orphan Drugs: A Cross‐Sectional Analysis of FDA and EMA Oversight
von: Jae Hyeon Yu, et al.
Veröffentlicht: (2024)

Impact of CYP2C19 Phenotype on Escitalopram Response in Geriatrics: Based on Physiologically‐Based Pharmacokinetic Modeling and Clinical Observation
von: Yoo Jin Jang, et al.
Veröffentlicht: (2024)

Identification and Clinical Evaluation of Potential Biomarkers for Breast Cancer Resistance Protein (BCRP/ABCG2)
von: Andrew M. Riselli, et al.
Veröffentlicht: (2025)

Navigating the Challenges of Cyclosporine as an Alternative to Rifampicin as an OATP1B Index Inhibitor
von: Manthena V. S. Varma, et al.
Veröffentlicht: (2025)

The Impact of QT‐Prolonging Medications and Drug–Drug Interactions on QTc Interval Prolongation in Hospitalized Patients: A Case‐Crossover Study
von: Hsiu‐Ting Chien, et al.
Veröffentlicht: (2024)

Predicting Maternal and Fetal Exposures of Elexacaftor–Tezacaftor–Ivacaftor during Pregnancy through Physiologically Based Pharmacokinetic Models
von: Eunjin Hong, et al.
Veröffentlicht: (2025)

Prognostic Implication of CYP2C19 Genotype According to Clinical Risk Stratification After Drug‐Eluting Stent Implantation
von: Hyun Woong Park, et al.
Veröffentlicht: (2025)

A Review of Virtual Twins in Physiologically‐Based Pharmacokinetic Modeling and Simulation
von: Emily Mannix, et al.
Veröffentlicht: (2026)

Population Pharmacokinetic Modeling and Exposure–Response Analysis for the Antibody–Drug Conjugate Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Carcinoma
von: Peiying Zuo, et al.
Veröffentlicht: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
von: Niels A. D. Guchelaar, et al.
Veröffentlicht: (2024)

Effects of Cimetidine and Dolutegravir on the Endogenous Drug–Drug Interaction Biomarkers for Organic Cation Transporter 2 and Multidrug and Toxin Extrusion Protein 1 in Healthy Volunteers
von: Tomoki Koishikawa, et al.
Veröffentlicht: (2024)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
von: Yue Zhu, et al.
Veröffentlicht: (2025)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
von: Amitava Mitra, et al.
Veröffentlicht: (2024)

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer
von: Mark J. Ratain
Veröffentlicht: (2024)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
von: Sachiko Mita, et al.
Veröffentlicht: (2025)